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Summary Multidrug resistance (MDR) is one of the mechanisms of resistance to multiple cytotoxic drugs
and is mediated by the expression of a membrane pump called the P-glycoprotein. Nifedipine is one of the
calcium channel blocking agents which reverses MDR in vitro. Fifteen patients with various malignancies
received nifedipine at three dose levels: 40 mg, 60 mg and 80 mg orally twice daily for 6 days. Etoposide was
administered intravenously on day 2 in a dose of 150-250 mg m 2 and orally 150-300 mg twice daily on days
3 and 4. Cardiovascular effects of nifedipine were dose limiting and the maximum tolerated dose was 60 mg
bid. Mean area under the plasma concentration curve (AUCo-0o) and plasma half-life (p) of nifedipine and its
major metabolite MI at the highest dose level were 7.87 pM.h, 7.97 h and 4.97 LM.h, 14.0 h respectively.
Nifedipine did not interfere with the pharmacokinetics of etoposide.
Resistance to chemotherapy precludes successful therapy of
most solid tumours. One mechanism of resistance to multiple
cytotoxics is multidrug resistance or MDR and is mediated
by an energy dependent efflux membrane pump. It is charac-
terised by the expression of P-glycoprotein (P-gp) on the
surface of malignant cells. Once resistance occurs it is
exhibited against a range of cytotoxics including vinca alka-
loids, epidopophyllotoxins, anthracyclines, and colchicine
(Moscow & Cowan, 1988). In vitro studies have shown that
the expression of the P-gp is strongly correlated with reduced
intracellular accumulation of cytotoxic drugs and resistance
to their action (Endicott & Ling, 1989). It has now been
shown that several human tumours express P-gp and this
may especially be apparent in tumours derived from tissues
that normally express high levels of P-gp (e.g. kidney) (Bell et
al., 1985; Fojo et al., 1987; Gerlach et al., 1987; Ma et al.,
1987). It has also been shown that some haematological
malignancies which progress after an initial response to
chemotherapy, show significantly increased expression of P-
gp compared to pre-treatment levels and may exhibit an
improved response with the use of verapamil as modifier of
MDR (Dalton et al., 1989).
Several drugs act as modulators of MDR by competitively
binding to P-gp and inhibiting the efflux of cytotoxic drugs
from the cells. To achieve reversal of MDR in vivo may
however require doses of modulators near to or even exceed-
ing the maximum tolerated doses of those drugs leading to
unacceptable toxicity. However, short term use of modifiers
may allow higher levels to be achieved temporarily. In addi-
tion to the dose of the modifier, the extent of plasma protein
binding determines the available free fraction of drugs for
competitive binding to the P-gp. In one previous study the
extent of binding of a modulator to al-acid glycoprotein was
inversely related to the reduction in the reversal of MDR in
vitro (Chatterjee et al., 1990). In addition to modification of
MDR, modifiers of drug resistance may be effective through
other potential mechanisms. It is also important to consider
the role of metabolites in MDR modulation (Merry et al.,
1989) and potential pharmacokinetic and pharmacodynamic
interactions between MDR modifiers and cytotoxic drugs
(Kerr et al., 1986).
Nifedipine is a dihydropyridine calcium channel blocker
commonly used in the treatment of ischaemic heart disease
and hypertension. It is metabolised in the liver by the micro-
somal mixed function oxidase, cytochrome P-450 IIIA, to the
pyridine metabolite M I (Schellens et al., 1988). Protein bind-
ing of nifedipine is 92-98%.
Etoposide is a broad spectrum cytotoxic drug whose bio-
transformation is partly dependent on the cytochrome P-450
dependent microsomal enzymes (Haim et al., 1987). DNA
damage and cytotoxicity correlate well with the intracellular
concentrations of etoposide. Yalowich and Ross (1985)
showed that verapamil increased the intracellular levels of
etoposide in L1210 cells in vitro, and this elevation of levels
was linearly correlated with enhancement of DNA damage
and cytotoxicity. The increase in the intracellular levels was
due to inhibition of efflux of etoposide from the cells. Chao
et al. (1990) showed that cyclosporin increases the cytotox-
icity of etoposide to MDR expressing leukaemic cells by
nearly 20-fold.
Nifedipine was chosen for this study because: (1) relative
lack of cardiac toxicity compared to verapamil which has
been commonly employed in modulating MDR in clinical
studies, (2) nifedipine may reverse MDR at concentrations
which may be achiveable in vivo (Mickisch et al., 1990), (3)
nifedipine may reverse resistance to cytotoxics (e.g. cisplatin)
by other mechanisms as well as reversal of MDR (Onoda et
al., 1986).
The aims of this phase I study were to determine (1) the
maximum tolerated dose of nifedipine in patients receiving
single agent etoposide, (2) pharmacokinetics of nifedipine at
the different dose levels, (3) pharmacodynamic and pharma-
cokinetic interactions between nifedipine and etoposide and
(4) tumour response.
Materials and methods
Patients
Approval to conduct this study was granted by The Central
Oxford Research Ethical Committee. Fifteen patients (nine
males and six females) with a mean age of 46.2 years (28-69
years), participated in this study after giving informed con-
sent. Patients had a performance status of ECOG 0-2 and
no history of cardiovascular disease. An electrocardiogram
was performed on all patients prior to entry into the study in
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order to exclude patients with recent myocardial ischaemia or
conduction defects.
Patients had histologically confirmed malignancy: renal cell
carcinoma five, breast carcinoma three, hepatocellular carcin-
oma 3, ovarian adenocarcinoma two, melanoma one, soft
tissue sarcoma one. Eight patients had received prior chemo-
therapy, and four had received hormonal treatment.
Treatment
Nifedipine slow release (Bayer, UK) was administered orally
for 6 days at three dose levels: 40mgbid, 60mgbid and
80 mg bid. If one dose level was tolerated well then the dose
was escalated with only one escalation allowed per patient.
To assess any interactions between nifedipine and etoposide,
nifedipine on days 1 and 2 was omitted from either.the first
or second course of therapy.
Etoposide (Vepesid, Bristol-Myers-Squibb, USA) was
administered at a starting dose of 150 mg m-2 in 1/21 normal
saline 0.9% intravenoulsy (i.v.) over 45 min on day 2, 2 h
from the previous dose of nifedipine, followed by 150 mg bid
po on days 3 and 4.
The plan was to increase the dose of etoposide after six
patients have been treated without evidence of significant
toxicity. The dose of etoposide was escalated to 200 mg m-2
i.v. on day 2 and 200-300 mg bid po on days 3 and 4.
Treatment was administered on outpatient basis except for
the intravenous etoposide which necessitated an overnight
admission to hospital.
Etoposide pharmacokinetics
Etoposide pharmacokinetics were determined following intra-
venous administration of two courses of treatment given with
and without nifedipine. Ten ml of venous blood was with-
drawn at mid-infusion and then 0 min, 15 min, 30 min, 45
min, 60 min, 2 h, 4 h, 6 h, 9 h, 12 h and 24 h from the end of
the infusion. Plasma was immediately separated and stored at
-20°C pending analysis. Etoposide levels were determined
by reverse-phase high-performance liquid chromatography
with UV detection (Harvey et al., 1985). Pharmacokinetic
parameters were derived using STRIPE, an interactive com-
puter programme (Johnson & Woollard, 1983). The area
under the plasma concentration curve was extrapolated to
infinity.
Nifedipine pharmacokinetics
Nifedipine pharmacokinetics were determined following the
third dose of nifedipine of the first course of treatment to
allow for the attainment of a near-steady concentration in
plasma. Venous blood was obtained 2, 3, 4, 6, and 8 h
post-dosing. Ten ml of blood were collected into a hepar-
inised tube protected from light with aluminum foil. Plasma
was separated under sodium lighting and stored at - 20°C
pending analysis. Nifedipine and the MI metabolite were
determined by capillary gas chromatography using a modifi-
cation of the method of Schmid et al. (1988). Pharmaco-
kinetic analysis was performed using an in-house computer
programme (N. Oates, St Mary's Hospital, London) fitting
the data into a non-linear two-compartment model. Area
under plasma concentration (AUC) of nifedipine and its MI
metabolite were extrapolated to infinity (AUCo-oo) using the
respective half-life values.
Statistical analysis
The pharmacokinetic parameters ofetoposide in the group of
ten patients studied with and without nifedipine were com-
pared using the Wilcoxon signed ranks matched pairs test.
Statistical significance was taken at a P value of <0.05.
Results
Nifedipinepharmacokinetics
Table I shows the peak plasma concentration, AUCo0o and
plasma half-life (,) of nifedipine and its MI metabolite at the
three dose levels. Peak plasma concentrations of nifedipine
were 0.45 JAM, 0.60 JLM and 0.66gAM for the three dose levels.
Peak MI metabolite concentration in plasma were 0.41 JiM,
0.38 JAM and 0.47 JAM at the corresponding dose levels.
Etoposidepharmacokinetics and interactions with nifedipine
Pharmacokinetic parameters of etoposide following intra-
venous administration were studied in ten patients for any
possible interactions with nifedipine (Table II). The terminal
half-life (,), AUCsO-, AUC-0/l00 mg dose, total plasma
clearance (Cl), and volume of distribution (Vd) of etoposide
were similar to those observed in a larger population study
(Joel S., personal communication). Pre-treatment with nife-
dipine did not significantly alter any of those parameters
implying lack of pharmacokinetic interactions between the
two drugs (P> 0.05).
Nifedipine toxicity
The side-effects of nifedipine which were represented the
dose-limiting end-points were severe headaches, postural
hypotension and postural dizziness. Severe headache was that
requiring regular analgesia and markedly interfering with the
normal daily routine. Dose-limiting postural hypotension was
defined as >20mmHg drop in the systolic blood pressure
when assuming the upright posture with or without postural
dizziness. Postural dizziness was defined as the sensation of
light-headedness particularly associated with the upright pos-
ture which interfered with normal activity.
TableII Comparison ofetoposide(Et)pharmacokineticparametersin
ten patients investigated with and without nifedipine (NF)
Parameter Et alone Etplus NF P (Wilcoxon)
i T1/2 (h) 4.67 (±1.3) 4.7 (±1.5) 0.61
AUCO.0/100 mg 55.8 (±17.2) 50.78 (±16.4) 0.31
(mg/ml.h)
Cl (ml/min) 35.2 (± 18.6) 37.3 (± 17.7) 0.42
Vd (L) 13.1 (±4.2) 14.1 (±4.5) 0.58
Mean values are given with standard deviations in parentheses.
Table I Pharmacokinetic parameters of nifedipine and its MI metabolite in ten patients after the oral
administration of nifedipine slow release preparation
Nifedipine MI metabolite
Dose n AUCOo. TJ/2(p) C.. A AUCo0oo T1/2(p)
(AM) (jaM.h) (h) (AM) (jIM.h) (h)
40 mg bid 2 0.45 2.86 4.35 0.41 3.06 19.7
(0.39-0.50) (2.45-3.26) (3.7-5.0) (0.22-0.59) (2.74-3.38) (2.3-37.0)
60 mg bid 5 0.60 7.02 8.77 0.38 2.39 8.5
(0.40-0.70) (2.58-19.0) (3.6- 19.3) (0.18-0.61) (0.92-4.93) (2.8-23.9)
80 mg bid 3 0.66 7.87 7.97 0.47 4.97 14.0
(0.42-0.80) (4.01-14.1) (3.0-12.2) (0.36-0.55) (2.21-7.1) (2.0-25.8)
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Seven, five and two patients were entered into the 40 mg,
60 mg and 80 mg dose levels respectively. The dose of nife-
dipine was escalated in four patients who were entered at the
40 mg and 60 mg dose levels respectively. The number of
courses of nifedipine at each of the three doses were 14, 13
and 8 respectively. Following dose escalations, eight, eight
and six patients were treated at each of the those dose levels
respectively. None of the eight subjects who received nife-
dipine at the 40 mg dose level experienced side effects, while
one out of eight patients on the 60 mg dose level experienced
symptomatic postural hypotension necessitating either a dose
reduction of nifedipine. Three of the six patients on the
80 mg dose level experienced significant toxicity which neces-
sitated dose reductions in one and discontinuation of nife-
dipine in two (Table III). The degree of toxicity at the 80 mg
dose level indicated that the maximum tolerated dose (MTD)
of nifedipine in an outpatient setting is 60mg bid.
Combination toxicity
Two patients were withdrawn from analysis due to early
death due to disease progression after one course of chemo-
therapy and before proper evaluation for toxicity. There were
no treatment related deaths and overall toxicity was moder-
ate and expected with the dose and schedule of etoposide
employed. Only two patients had severe myelosuppression
complicated by sepsis. Side effects related to modulation of
MDR in normal tissues (e.g. diarrhoea) were absent. Table
IV gives details of combination toxicity in the nine patients
who received the higher dose of etoposide.
Response
Of the 15 patients studied 12 exhibited progressive disease,
two had stable disease with a mean duration of 2 months,
one patient achieved a mixed response, with partial remission
in lung metastases and disease progression in the orbital
cavity.
Discussion
Peak plasma concentrations of nifedipine achieved in this
study were less than 1 gM. In vitro work on the modulation
of MDR by nifedipine has employed concentrations above
5,M in cell lines exhibiting levels of resistance which are
probably much higher than those encountered in clinical
conditions (Kessel & Wilberding, 1984; Willingham et al.,
1986). However, it has recently been demonstrated by Mick-
isch et al. (1990) that concentrations of nifedipine as low as
1 jAM could significantly enhance cytotoxicity by vinblastine
in vitro to cells from fresh human renal cell carcinoma.
Concentrations up to 0.47 jAM of the MI metabolite were
achieved in plasma. There is no information on the activity
of this metabolite in reversing MDR in vitro. If it was
possible to show modulation of MDR by the MI metabolite
then this would increase the effective plasma concentrations
to modulate MDR by 50%. Further studies are required to
ascertain the contribution of the MI metabolite to the rever-
sal of MDR in vitro since relatively significant plasma con-
centrations are achieved. The half-life of the MI metabolite
was shorter in some of the patients and that may be
explained on the basis of metabolism by enzymes different to
those metabolising nifedipine.
Verapamil is another calcium channel blocker which has
been clinically investigated for its MDR modulating proper-
ties. Unfortunately its clinical use has been associated with
signifciant cardiovascular toxicity in the form of hypotension
and/or prolonged atrioventricular conduction time. There
was also interaction with the clearance of doxorubicin (Kerr
et al., 1986). The present study shows that cardiovascular
(i.e. calcium blocking) effects of nifedipine are the dose-
Table III Nifedipine toxicity profile in patients at the three dose levels
who experienced severe toxicity
Dose
Dose (bid) n Hypoten Dizziness Headache reduct
40mg 8 0 0 0 0
60mg 8 1 2 1 1
80mg 6 2 3 3 2
TableIV Toxicity dataon thecombination therapyinninepatients on
the higher dose level ofetoposide
WHO Grade
Toxicity 0 1 2 3 4
Anaemia 6 2 1 0 0
Leucopenia 2 2 2 2 1
Thrombocytopenia 8 0 0 1 0
Infection 7 0 1 1 0
Alopecia 2 1 5 1 0
Nausea/Vomiting 8 0 1 0 0
Diarrhoea 9 0 0 0 0
limiting factor in therapy. Toxicity of nifedipine is clearly
dose related (Table IV) and the maximum tolerated dose of
nifedipine for future studies should be 60 mg bid in an
outpatient setting.
Etoposide was commenced on day 2 of the cycle because it
was intended to treat the patient with nifedipine for the least
possible time to minimise toxicity. With the calculated nife-
dipine plasma half-life of 6-8 h, approximately 90% of the
steady plasma concentrations are expected to occur within
26 h of starting nifedipine. The starting dose of etoposide
was chosen on the bais of patient safety in order to avoid
unexpected synergy with nifedipine. After the initial cohort
of six patients it was considered safe to escalate the dose of
etoposide because it is prudent to investigate modulation of
etoposide toxicity by nifedipine at therapeutic doses ofetopo-
side.
There was no change in the pharmacokinetic parameters of
etoposide when used in combination with nifedipine. There is
also no indication in this study that nifedipine has poten-
tiated the toxicity of etoposide. In particular there were no
features suggesting increased toxicity of etoposide to tissues
rich in P-gp such as the gastrointestinal tract. Detailed
studies to investigate cardiac toxicity were not performed as
the dose limiting toxicity of nifedipine was due to symptoms
predicted from its mode of action. We did not undertake
detailed cardiac investigations to determine interactions
between etoposide and nifedipine because cardiotoxicity due
to etoposide is very unusual. Nifedipine on the other hand
has no obvious effect on atrioventricular conduction com-
pared to verapamil (Rowland et al., 1979).
There were no tumour responses in this present phase I
study except for one patient with breast carcinoma who had
a mixed response. Response to etoposide would be expected
to depend on (a) response of the tumour type to the chemo-
therapy used, (b) degree of importance of MDR in drug
resistance in the tumours studied, (c) achievement of plasma
nifedipine levels sufficient to reverse MDR, and (d) the con-
tribution of other mechanisms of resistance to etoposide such
as reduced topoisomerase II activity tumour cells (Beck,
1989).
Hu et al. (1990) have shown that cyclosporin and verap-
amil exhibited synergism in reversing MDR in vitro at con-
centrations normally seen in clinical situations. In future
studies a combination of MDR modulators may potentially
be employed, each with different dose limiting toxicity to test
whether there would be synergy in their modification of
MDR.270 P.A. PHILIP et al.
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